Champions Oncology was founded in 2007 and is headquartered in Hackensack, US

CEO

President

Director

Involved

Champions Oncology has offices in Hackensack, Baltimore and London

Hackensack, US (HQ)

307 1 University Plaza Dr

London, GB

2 Royal College St

Baltimore, US

602 855 N Wolfe St

Champions Oncology's revenue was reported to be $11.2 m in FY, 2016 which is a **26% increase** from the previous period.

USD

## Revenue (FY, 2016) | 11.2 m |

## Revenue growth (FY, 2015 - FY, 2016), % | 26% |

## Net income (FY, 2016) | (10.4 m) |

## EBIT (FY, 2016) | (10.3 m) |

## Market capitalization (21-Jul-2017) | 29 m |

## Cash (31-Jan-2017) | 3.5 m |

Champions Oncology's current market capitalization is $29 m.

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Revenue | 11.6 m | 8.9 m | 11.2 m |

## Revenue growth, % | (23%) | 26% | |

## Sales and marketing expense | 3.4 m | ||

## R&D expense | 4.2 m | ||

## General and administrative expense | 5.2 m | ||

## Operating expense total | 17.8 m | 22.1 m | 21.5 m |

## EBIT | (6.3 m) | (13.2 m) | (10.3 m) |

## EBIT margin, % | (54%) | (149%) | (92%) |

## Net Income | (7.4 m) | (13.1 m) | (10.4 m) |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Cash | 5.9 m | 9.4 m | |

## Accounts Receivable | 1.3 m | 1.1 m | 1.3 m |

## Inventories | 383 k | 346 k | 443 k |

## Current Assets | 7.6 m | 10.8 m | 4.3 m |

## PP&E | 434 k | 452 k | 618 k |

## Goodwill | 669 k | 669 k | 669 k |

## Total Assets | 8.9 m | 12 m | 5.8 m |

## Accounts Payable | 981 k | 1.4 m | 1.9 m |

## Current Liabilities | 3.7 m | 3.8 m | 5.3 m |

## Total Liabilities | 5.5 m | ||

## Additional Paid-in Capital | 43.3 m | 61.2 m | 63.9 m |

## Retained Earnings | (38.9 m) | (52 m) | (62.5 m) |

## Total Equity | 3.2 m | 8.1 m | 238 k |

## Financial Leverage | 2.8 x | 1.5 x | 24.3 x |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 3.1 m | 575 k | 182 k | 6.8 m | 4.2 m | 3.3 m | 4.5 m | 4.3 m | 3.5 m |

## Accounts Receivable | 925 k | 1.1 m | 1.1 m | 1.5 m | 1.9 m | 2.1 m | 1.6 m | 1.9 m | 2 m |

## Current Assets | 4.4 m | 2.1 m | 1.5 m | 8.6 m | 6.3 m | 5.8 m | 6.4 m | 6.7 m | 6.1 m |

## PP&E | 411 k | 395 k | 469 k | 445 k | 420 k | 514 k | 590 k | 561 k | 672 k |

## Goodwill | 669 k | 669 k | 669 k | 669 k | 669 k | 669 k | 669 k | 669 k | 669 k |

## Total Assets | 5.7 m | 3.3 m | 2.8 m | 9.8 m | 7.6 m | 7.1 m | 7.8 m | 8 m | 7.5 m |

## Accounts Payable | 1.3 m | 1.6 m | 1.4 m | 1.4 m | 1.3 m | 1.5 m | 1.5 m | 1.2 m | 1.3 m |

## Current Liabilities | 3.4 m | 3.9 m | 6.3 m | 3.8 m | 3.3 m | 4.6 m | 4.4 m | 4.6 m | 5.3 m |

## Additional Paid-in Capital | 44.1 m | 44.9 m | 45.4 m | 62.1 m | 62.8 m | 63.4 m | 69.4 m | 70 m | 70.2 m |

## Retained Earnings | (42.4 m) | (45.6 m) | (48.4 m) | (54.9 m) | (57.5 m) | (59.9 m) | (65 m) | (65.5 m) | (66.9 m) |

## Total Equity | 439 k | 5.9 m | 4.1 m | 2.3 m | 3.2 m | 3.2 m | 2 m | ||

## Financial Leverage | 12.9 x | 1.7 x | 1.8 x | 3.2 x | 2.5 x | 2.5 x | 3.7 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Net Income | (7.4 m) | (13.1 m) | (10.4 m) |

## Depreciation and Amortization | 213 k | 214 k | 156 k |

## Accounts Receivable | (825 k) | 265 k | (282 k) |

## Accounts Payable | (223 k) | 433 k | 482 k |

## Cash From Operating Activities | (3.4 m) | (9.6 m) | (6.5 m) |

## Purchases of PP&E | (234 k) | (119 k) | (322 k) |

## Cash From Investing Activities | (234 k) | (114 k) | (322 k) |

## Cash From Financing Activities | 21 k | 13.2 m | 2 k |

USD | Q1, 2014^{} | Q2, 2014^{} | Q3, 2015^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2016^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Accounts Receivable | 925 k | 1.1 m | 1.1 m | 1.5 m | 1.9 m | 2.1 m | 1.6 m | 1.9 m | 2 m |

## Accounts Payable | 1.3 m | 1.6 m | 1.4 m | 1.4 m | 1.3 m | 1.5 m | 1.5 m | 1.2 m | 1.3 m |

Y, 2017 | |
---|---|

## Financial Leverage | 3.7 x |